Peptide T

Phase 2Peptide

NNational Institute of Mental Health (NIMH)

Peptide T is one of 128 small molecule programs targeting Cognitive impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Peripheral NeuropathyActive, not recruiting

ImmunodeficiencyActive, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

ImmunodeficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Viread

Gilead

Phase 3

1 2

Retrovir

BBp Consulting, Inc

Phase 3

6 3

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

1 4

Immunoglobulin

Sanofi

Phase 3

2 5

Prevnar 13

Merck & Co.

Phase 3

2 6

FTC/TDF

Gilead

Phase 3

1 7

BIC/FTC/TAF

Merck & Co.

Phase 3

5 8

Darunavir/ritonavir

GSK

Phase 3

1 9

BI201335

Boehringer Ingelheim

Phase 3

1 10

Rosuvastatin and Ezetimibe

Hanmi Pharmaceutical Company Limited

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency2 trials

A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00000393·6 enrolled

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

Completed·NNational Institute of Mental Health (NIMH)·Phase 1·NCT00000391·30 enrolled

Cognitive impairment1 trial

Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00000392·215 enrolled

Peripheral Neuropathy1 trial

Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

Completed·AAdvanced Peptides·N/A·NCT00002083

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Peptide T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Mental Health (NIMH)

Peptide T

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency2 trials

Cognitive impairment1 trial

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News